Risk Prediction and Management of BKPyV-DNAemia in Kidney Transplant Recipients: A Multicenter Analysis of Immunosuppressive Strategies

Risk Prediction and Management of BKPyV-DNAemia in Kidney Transplant Recipients: A Multicenter Analysis of Immunosuppressive Strategies

BK polyomavirus (BKPyV) DNAemia remains a major complication in kidney transplantation (KT), requiring nuanced adjustments to immunosuppressive regimens to control viral replication while minimizing rejection risk. This retrospective multicenter cohort study included 8,027 KT recipients, of whom 1,1...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jin-Myung Kim, Hye Eun Kwon, Ahram Han, Youngmin Ko, Sung Shin, Young Hoon Kim, Kyo Won Lee, Jae Berm Park, Hyunwook Kwon, Sangil Min
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Transplant International
Subjects:	kidney transplantation Bk virus immunosuppressive therapy calcineurin inhibitor tacrolimus trough level
Online Access:	https://www.frontierspartnerships.org/articles/10.3389/ti.2025.14738/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Combined standard immunosuppression and immune checkpoint inhibition for BKPyV+ metastatic renal cell carcinoma of the graft in a kidney transplant recipient with chronic rejection: a case report
by: Ilaria Gandolfini, et al.
Published: (2025-03-01)

The association between serum tacrolimus concentrations and BK viruria in kidney transplant recipients
by: Napatsorn Kraivisitkul, et al.
Published: (2025-01-01)

Use of tacrolimus to prevent acute kidney graft rejection in sensitized patients
by: O. N. Rzhevskaya, et al.
Published: (2018-08-01)

Modification of immunosuppressive agents in a kidney transplant recipient with COVID-19 and acute kidney injury
by: Thanawat Vongchaiudomchoke, et al.
Published: (2021-09-01)

FIRST EXPERIENCE IN SYSTEMIC ADMINISTRATION OF EVEROLIMUS IN RENAL TRANSPLANTATION FROM EXPANDED CRITERIA DONORS IN RUSSIAN FEDERATION
by: I. V. Uliyankina, et al.
Published: (2017-01-01)

TACROLIMUS ASSOCIATED HEMORRHAGIC POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME: A RARE CASE IN THE LATE PERIOD AFTER RENAL TRANSPLANTATION
by: Yasemin Akıncı, et al.
Published: (2022-07-01)

Evaluation of the results of treatment of kidney recipients at the outpatient stage against the background of minimizing immunosuppressive therapy
by: E. V. Parabina, et al.
Published: (2023-10-01)

Changes in glomerular filtration rate in liver recipients after reduced exposure to calcineurin inhibitors with concomitant everolimus administration within the first year after immunosuppression conversion
by: V. E. Syutkin, et al.
Published: (2022-01-01)

Clinical laboratory aspects of one-component immunosuppression during liver transplantation
by: M. Sh. Khubutia, et al.
Published: (2018-08-01)

Ethnic differences in early blood tacrolimus concentrations after kidney transplantation: a retrospective observational study
by: Eilidh C. Thomas, et al.
Published: (2025-08-01)

Calcineurin‐inhibitor induced pain syndrome due to interaction with clarithromycin: A case report
by: Satoshi Inaba, et al.
Published: (2025-03-01)

Approaches to correction of immunosuppressive therapy in chronic nephrotoxicity of calcineurin inhibitors
by: E. S. Stolyarevich, et al.
Published: (2018-08-01)

Transplant failure in relation to BK viremia status among kidney transplant recipients in Jordan
by: Rabaa Y. Athamneh, et al.
Published: (2025-07-01)

Personalized dosing protocol for extended-release tacrolimus in kidney transplant recipients in the early postoperative period
by: A. V. Shabunin, et al.
Published: (2023-04-01)

Calcineurin–NFAT signalling in myeloid leucocytes: new prospects and pitfalls in immunosuppressive therapy
by: Kamila Bendickova, et al.
Published: (2017-06-01)

Pharmacoeconomic analysis of everolimus immunosuppressive therapy for <i>de novo</i> kidney transplant recipients in Russia
by: N. A. Avxentyev, et al.
Published: (2019-05-01)

The effect of early everolimus administration on the renal function while reducing the dosage of calcineurin inhibitors in liver transplant recipients in a long-term follow-up
by: V. E. Syutkin, et al.
Published: (2021-06-01)

Tacrolimus for Ophthalmic Use: An Update
by: Sana Ilias Tinwala, et al.
Published: (2013-01-01)

Clinical and molecular analysis of JCPyV and BKPyV infection and associated risk of urothelial carcinoma development in the upper tract
by: Chun-Nun Chao, et al.
Published: (2025-02-01)

A Case of Repeat Kidney Transplant Intolerant to Multiple First-line Immunosuppressive Agents Mycophenolate Mofetil, Azathioprine, and Calcineurin Inhibitors
by: Puneet Arora, et al.
Published: (2024-12-01)

Tremors and Health-Related Quality of Life in Liver Transplant Recipients: Post-hoc Analysis of a Multicenter, Randomized, Controlled Trial Comparing a Life Cycle Pharma-Tacrolimus Regimen and Extended-Release Tacrolimus Regimen
by: M. B. Mulder, et al.
Published: (2025-04-01)

On the interchangeability of calcineurine inhibitors
by: K. E. Zatolochina, et al.
Published: (2018-02-01)

Allogeneic CD4 T Cells Sustain Effective BK Polyomavirus-Specific CD8 T Cell Response in Kidney Transplant Recipients
by: Manon Dekeyser, et al.
Published: (2024-08-01)

Conversion to everolimus to preserve kidney function in a heart transplant recipient, a personalized approach of immunos uppressive therapy
by: N. N. Koloskova, et al.
Published: (2018-09-01)

Immunosuppressive drugs and their aerosol delivery for COVID-19 treatment
by: V. I. Kobylyansky
Published: (2022-10-01)

Development of BK polyomavirus-associated nephropathy risk prediction in kidney transplant recipients
by: Junji Yamauchi, et al.
Published: (2025-12-01)

Belatacept-based immunosuppression in heart transplant recipients: A single center experience
by: Wairimu Magua, PhD, MS, et al.
Published: (2025-08-01)

<i>PPP3R1</i> Promoter Polymorphism (Allelic Variation) Affects Tacrolimus Treatment Efficacy by Modulating E2F6 Binding Affinity
by: Xinyi Zheng, et al.
Published: (2024-12-01)

MEDICAMENTAL IMMUNOSUPRESSION IN EARLY AGE PEDIATRIC LIVER RECIPIENTS
by: S. V. Gautier, et al.
Published: (2012-09-01)

Early CYP3A5 Genotype-Based Adjustment of Tacrolimus Dosage Reduces Risk of De Novo Donor-Specific HLA Antibodies and Rejection among CYP3A5-Expressing Renal Transplant Patients
by: Kristina Schönfelder, et al.
Published: (2024-10-01)

Comparative analysis of induction immunosuppressive therapy protocols in renal transplant recipients (retrospective review)
by: Sh. R. Galeev, et al.
Published: (2020-07-01)

Effect of cyclosporin A on respiratory viral replication in fully differentiated ex vivo human airway epithelia
by: Louise Bondeelle, et al.
Published: (2024-10-01)

The role of calcineurin inhibitors in the progression of hepatocellular carcinoma after liver transplantation
by: O. D. Olisov, et al.
Published: (2022-09-01)

Decreased calcineurin immunoreactivity in the postmortem brain of a patient with schizophrenia who had been prescribed the calcineurin inhibitor, tacrolimus, for leukemia
by: Wada A, et al.
Published: (2016-07-01)

Intrapatient tacrolimus variability is associated with medical nonadherence among pediatric kidney transplant recipients
by: Tara B. Gavcovich, et al.
Published: (2025-03-01)

BK Virus: Beyond Nephropathy Metastatic BK Virus-Induced, Donor-Derived Bellini’s Carcinoma in a Kidney Allograft Recipient: Boosting Rejection to Treat the Cancer
by: Flora Lefevre, et al.
Published: (2025-07-01)

Analysis of risk factors for perioperative hyperamylasemia in kidney transplant recipients
by: Yang Zhang, et al.
Published: (2025-12-01)

Development of a droplet digital PCR assay for the detection of BK polyomavirus
by: Lu Ai, et al.
Published: (2024-11-01)

Kaposi’s sarcoma regression after long term treatment of m-TOR inhibitors and cancellation of immunosuppressive therapy in patient after kidney transplantation
by: A. D. Sapozhnikov, et al.
Published: (2019-07-01)

A national survey of immunosuppression adjustment in elderly lung transplant recipients
by: Jade M Kozuch, et al.
Published: (2024-12-01)